VRDN logo

Viridian Therapeutics (VRDN)

Profile

Full Name

Viridian Therapeutics, Inc.

Ticker Symbol

VRDN

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 18, 2014

Indexes

Not included

Website

http://www.viridiantherapeutics.com

Employees

143

Key Details

Price

$12.65

Market Cap

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$302.00K(-3.82% YoY)

Annual EPS

-$3.07(+21.48% YoY)

PE Ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$12.65
VRDN price is $12.65

Price All-time High

$2045.25
VRDN price is currently -99.38% below its historical high of $2045.25

Price Most Recent Change

-1.33%
VRDN price was down -1.33% on Apr 3, 2025

Price YTD Change

-33.07%
VRDN price is down -33.07% since January 1st

Price 1-year Change

-23.75%
VRDN price is down -23.75% year-on-year

Price 3-year Change

-32.28%
VRDN price is down -32.28% over the past 3 years

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market Cap

$1.03B
VRDN market capitalization is $1.03 billion

Market Cap 3-year Change

+103.1%
VRDN market capitalization is up +103.1% over the past 3 years

Market Cap All-time High

$2.04B
VRDN market capitalization is currently -49.39% below its historical high of $2.04 billion

Market Cap Sector Rank

76.37%
VRDN market capitalization is higher than 76.37% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+27.72%
VRDN shares outstanding is up +27.72% year-on-year

Shares Outstanding 3-Year Change

+199.91%
VRDN shares outstanding is up +199.91% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.23
VRDN beta is 1.23

200-day SMA

$18.06
VRDN price is currently -29.95% below its 200-day simple moving average

50-day SMA

$16.36
VRDN price is currently -22.68% below its 50-day simple moving average

RSI

31.40
VRDN 14-day relative strength index is 31.40

Volume

1.32
VRDN 30-day relative volume is 1.32

ATR

$0.80
VRDN average true range is $0.80

10-day Historical Volatility

62.24%
VRDN 10-day historical volatility is 62.24%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$302.00K
VRDN annual revenue is $302.00 thousand

Revenue Analysts Estimate

$160.29K
VRDN annual revenue is currently +88.41% higher than the consensus analysts' forecast

Revenue 1-year Change

-3.82%
VRDN annual revenue is down -3.82% year-on-year

Revenue Sector Rank

11.53%
VRDN annual revenue is higher than 11.53% of companies in Healthcare sector

EPS

EPS

-$3.07
VRDN annual earnings per share is -$3.07

EPS Analysts Estimate

-$4.04
VRDN annual earnings per share is currently -24.01% lower than the consensus analysts' forecast

EPS 1-year Change

+21.48%
VRDN annual earnings per share is up +21.48% year-on-year

EPS Sector Rank

28.28%
VRDN annual earnings per share is higher than 28.28% of companies in Healthcare sector

Profit

Gross Profit

-
VRDN annual gross profit value is unknown

Gross Margin

-
VRDN annual gross profit margin value is unknown

Operating Profit

-$299.04M
VRDN annual operating income is -$299.04 million

Operating Margin

-99.02K%
VRDN annual operating profit margin is -99.02 thousand%

Net Income

-$269.95M
VRDN annual net profit is -$269.95 million

Net Margin

-89.39K%
VRDN annual net profit margin is -89.39 thousand%

Expenses

Total Expenses

$299.34M
VRDN annual total expenses is $299.34 million

Operating Expenses

$299.34M
VRDN annual total operating expenses is $299.34 million

Cost Of Goods Sold

-
VRDN annual cost of goods sold value is unknown

Selling, General & Administrative Expenses

$61.08M
VRDN annual SGA is $61.08 million

Depreciation And Amortization

$540.00K
VRDN annual depreciation & amortization is $540.00 thousand

Interest Expense

$3.05M
VRDN annual interest expense is $3.05 million

Income Tax

-
VRDN annual income tax value is unknown

EBIT & EBITDA

EBIT

-$266.90M
VRDN annual earnings before interest & taxes is -$266.90 million

EBITDA

-$266.36M
VRDN annual EBITDA is -$266.36 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total Assets

$742.40M
VRDN annual total assets is $742.40 million

Non Current Assets

$3.94M
VRDN annual long term assets is $3.94 million

Current Assets

$738.46M
VRDN annual total current assets is $738.46 million

Cash And Cash Equivalents

$99.59M
VRDN annual cash & cash equivalents is $99.59 million

Accounts Receivable

-
VRDN annual accounts receivable value is unknown

Inventory

-
VRDN annual inventory value is unknown

Liabilities

Total Liabilities

$70.76M
VRDN annual total liabilities is $70.76 million

Long Term Liabilities

$22.89M
VRDN annual total long term liabilities is $22.89 million

Current Liabilities

$47.87M
VRDN annual total current liabilities is $47.87 million

Accounts Payable

$2.14M
VRDN annual accounts payable is $2.14 million

Debt

Total Debt

$21.09M
VRDN annual total debt is $21.09 million

Total Debt 1-year Change

+0.22%
VRDN annual total debt is up +0.22% year-on-year

Long Term Debt

$20.58M
VRDN annual long term debt is $20.58 million

Short Term Debt

$513.00K
VRDN annual short term debt is $513.00 thousand

Equity & Capital

Shareholders Equity

$671.64M
VRDN annual stockholders equity is $671.64 million

Book Value

$482.75M
VRDN annual book value is $482.75 million

Retained Earnings

-$995.86M
VRDN annual retained earnings is -$995.86 million

Working Capital

$690.59M
VRDN annual working capital is $690.59 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash From Operations

-$232.32M
VRDN annual cash flow from operations is -$232.32 million

Cash From Operations 1-year Change

-26.14%
VRDN annual cash flow from operations is down -26.14% year-on-year

Cash From Investing

-$228.65M
VRDN annual cash flow from investing activities is -$228.65 million

Cash From Investing 1-year Change

-142.6%
VRDN annual cash flow from investing activities is down -142.6% year-on-year

Cash From Financing

$457.74M
VRDN annual cash flow from financing activities is $457.74 million

Cash From Financing 1-year Change

+102.83%
VRDN annual cash flow from financing activities is up +102.83% year-on-year

CAPEX

CAPEX

$511.00K
VRDN annual capital expenditures is $511.00 thousand

CAPEX 1-year Change

-43.1%
VRDN annual capital expenditures is down -43.1% year-on-year

Free Cash Flow

Free Cash Flow

-$232.83M
VRDN annual free cash flow is -$232.83 million

Free Cash Flow 1-year Change

-25.81%
VRDN annual free cash flow is down -25.81% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross Margin

-
VRDN annual gross profit margin value is unknown

Operating Margin

-99.02K%
VRDN annual operating profit margin is -99.02 thousand%

Net Margin

-89.39K%
VRDN annual net profit margin is -89.39 thousand%

ROA & ROE

ROA

-43.79%
VRDN annual return on assets is -43.79%

ROE

-48.48%
VRDN annual return on equity is -48.48%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
VRDN price to earnings ratio value is unknown

PE Ratio Sector Rank

-
VRDN price to earnings ratio is unknown

PB Ratio

PB Ratio

2.14
VRDN price to book ratio is 2.14

PB Ratio Sector Rank

64.45%
VRDN price to book ratio is higher than 64.45% of companies in Healthcare sector

PS Ratio

PS Ratio

3413.20
VRDN price to sales ratio is 3413.20

PS Ratio Sector Rank

99.36%
VRDN price to sales ratio is higher than 99.36% of companies in Healthcare sector

Enterprise value

Enterprise Value

$952.29M
VRDN enterprise value is $952.29 million

Enterprise Value Sector Rank

74.86%
VRDN enterprise value is higher than 74.86% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.58
VRDN EV/EBITDA is -3.58

EV/EBITDA Sector Rank

23.63%
VRDN EV/EBITDA is higher than 23.63% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current Ratio

15.43
VRDN annual current ratio is 15.43

Quick Ratio

-
VRDN annual quick ratio value is unknown

Leverage

Debt To Equity

0.03
VRDN annual debt to equity ratio is 0.03

Interest Coverage Ratio

-87.62
VRDN annual interest coverage ratio is -87.62

Risk & Stability

Piotroski F-Score

-
VRDN piotroski f-score value is unknown

Altman Z-Score

6.79
VRDN altman z-score is 6.79

Analyst ratings

Recent major analysts updates

Jan 7, 25 Needham
Buy
Dec 19, 24 Wells Fargo
Equal-Weight
Dec 17, 24 RBC Capital
Outperform
Dec 17, 24 HC Wainwright & Co.
Buy
Dec 16, 24 HC Wainwright & Co.
Buy
Dec 5, 24 RBC Capital
Outperform
Nov 25, 24 TD Cowen
Buy
Nov 25, 24 Needham
Buy
Nov 14, 24 HC Wainwright & Co.
Buy
Nov 13, 24 Needham
Buy

Institutional Ownership

Similar stocks

ETNB logo
89bio (ETNB)
USPH logo
US Physical Therapy (USPH)
AVAH logo
Aveanna Healthcare Holdings (AVAH)
AORT logo
Artivion (AORT)
ADPT logo
Adaptive Biotechnologies (ADPT)
BLFS logo
BioLife Solutions (BLFS)
PLSE logo
Pulse Biosciences (PLSE)
MDXG logo
MiMedx (MDXG)
WVE logo
Wave Life Sciences (WVE)
  • What is the ticker symbol for Viridian Therapeutics?
  • Does Viridian Therapeutics pay dividends?
  • What sector is Viridian Therapeutics in?
  • What industry is Viridian Therapeutics in?
  • What country is Viridian Therapeutics based in?
  • When did Viridian Therapeutics go public?
  • Is Viridian Therapeutics in the S&P 500?
  • Is Viridian Therapeutics in the NASDAQ 100?
  • Is Viridian Therapeutics in the Dow Jones?
  • When was Viridian Therapeutics's last earnings report?
  • When does Viridian Therapeutics report earnings?
  • Should I buy Viridian Therapeutics stock now?

What is the ticker symbol for Viridian Therapeutics?

The ticker symbol for Viridian Therapeutics is NASDAQ:VRDN

Does Viridian Therapeutics pay dividends?

No, Viridian Therapeutics does not pay dividends

What sector is Viridian Therapeutics in?

Viridian Therapeutics is in the Healthcare sector

What industry is Viridian Therapeutics in?

Viridian Therapeutics is in the Biotechnology industry

What country is Viridian Therapeutics based in?

Viridian Therapeutics is headquartered in United States

When did Viridian Therapeutics go public?

Viridian Therapeutics's initial public offering (IPO) was on June 18, 2014

Is Viridian Therapeutics in the S&P 500?

No, Viridian Therapeutics is not included in the S&P 500 index

Is Viridian Therapeutics in the NASDAQ 100?

No, Viridian Therapeutics is not included in the NASDAQ 100 index

Is Viridian Therapeutics in the Dow Jones?

No, Viridian Therapeutics is not included in the Dow Jones index

When was Viridian Therapeutics's last earnings report?

Viridian Therapeutics's most recent earnings report was on Feb 27, 2025

When does Viridian Therapeutics report earnings?

The next expected earnings date for Viridian Therapeutics is May 8, 2025

Should I buy Viridian Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page